The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Trial of celecoxib in amyotrophic lateral sclerosis
Abstract
Objective: To determine whether chronic treatment with celecoxib, a cyclooxygenase‐2 inhibitor that has been shown to be beneficial in preclinical testing, is safe and effective in amyotrophic lateral sclerosis (ALS). Methods: A double‐blind, placebo‐controlled, clinical trial was conducted. Three hundred research subjects with ALS were randomized (2:1) to receive celecoxib (800mg/day) or placebo for 12 months. The primary outcome measure was the rate of change in upper extremity motor function measured by the maximum voluntary isometric contraction strength. Secondary end points included safety, survival, change in cerebrospinal fluid prostaglandin E 2 levels, and changes in the rate of decline of leg and grip strength, vital capacity, ALS Functional Rating Scale‐Revised, and motor unit number estimates. Results: Celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, ALS Functional Rating Scale‐Revised, or affect survival. Celecoxib was well tolerated and was not associated with an increased frequency of adverse events. Prostaglandin E 2 levels in cerebrospinal fluid were not elevated at baseline and did not decline with treatment. Interpretation: At the dosage studied, celecoxib did not have a beneficial effect on research subjects with ALS, and it was safe. A biological effect of celecoxib was not demonstrated in the cerebrospinal fluid. Further studies of celecoxib at a dosage of 800mg/day in ALS are not warranted. Ann Neurol 2006;60:22–31
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rothstein, J. D., Dykes-Hoberg, M., Pardo, C. A., Bristol, L. A., Jin, L., Kuncl, R. W., Kanai, Y., Hediger, M. A., Wang, Y., Schielke, J. P., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80086-0 · Cited by 2,534
Self-citationDose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V, Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,301
Prostaglandins stimulate calcium-dependent glutamate release in astrocytes
Bezzi, P., Carmignoto, G., Pasti, L., Vesce, S., Rossi, D., Rizzini, B. L., Pozzan, T., & Volterra, A. (1998) · Nature · doi:10.1038/34651 · Cited by 1,143
Functional Role of Caspase-1 and Caspase-3 in an ALS Transgenic Mouse Model
Li, M., Ona, V. O., Guégan, C., Chen, M., Jackson-Lewis, V., Andrews, L. J., Olszewski, A. J., Stieg, P. E., Lee, J.-P., Przedborski, S., et al. (2000) · Science · doi:10.1126/science.288.5464.335 · Cited by 716
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis
Rothstein, J. D., Tsai, G., Kuncl, R. W., Clawson, L., Cornblath, D. R., Drachman, D. B., Pestronk, A., Stauch, B. L., & Coyle, J. T. (1990) · Annals of Neurology · doi:10.1002/ana.410280106 · Cited by 636
Self-citationCloning Two Isoforms of Rat Cyclooxygenase: Differential Regulation of Their Expression
Feng, L., Sun, W. Q., Xia, Y. Y., Tang, W. W., Chanmugam, P., Soyoola, E., Wilson, C. B., & Hwang, D. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1601 · Cited by 452
(1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550020045014 · Cited by 415
Neuroprotective Function of the PGE2EP2 Receptor in Cerebral Ischemia
McCullough, L., Wu, L., Haughey, N., Liang, X., Hand, T., Wang, Q., Breyer, R. M., & Andreasson, K. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4485-03.2004 · Cited by 361
Self-citationIncreased oxidative damage to DNA in ALS patients
Bogdanov, M., Brown, R. H., Matson, W., Smart, R., Hayden, D., O’Donnell, H., Flint Beal, M., & Cudkowicz, M. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00349-x · Cited by 334
Self-citation
Cited by
Mechanisms underlying inflammation in neurodegeneration
Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580
ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors
Boillée, S., Vande Velde, C., & Cleveland, D. W. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.018 · Cited by 1,429
Microglia polarization from M1 to M2 in neurodegenerative diseases
Guo, S., Wang, H., & Yin, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.815347 · Cited by 920
Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease
Philips, T., & Robberecht, W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70015-1 · Cited by 646
Henkel, J. S., Engelhardt, J. I., Siklós, L., Simpson, E. P., Kim, S. H., Pan, T., Goodman, J. C., Siddique, T., Beers, D. R., & Appel, S. H. (2004) · Annals of Neurology · doi:10.1002/ana.10805 · Cited by 559
Metadata
- Authors
- Cudkowicz, M. E., Shefner, J. M., Schoenfeld, D. A., Zhang, H., Andreasson, K. I., Rothstein, J. D., Drachman, D. B., & Northeast ALS Consortium
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2006-06-26
- Volume
- 60
- Issue
- 1
- Pages
- 22-31
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2097367691
- Cited by
- 301
- References
- 36
- FWCI
- 13.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trial of celecoxib in amyotrophic lateral sclerosis. https://app.cochat.ai/papers/10.1002/ana.20903
- The paper
- Cudkowicz, M. E., Shefner, J. M., Schoenfeld, D. A., Zhang, H., Andreasson, K. I., Rothstein, J. D., Drachman, D. B., & Northeast ALS Consortium. (2006). Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology. https://doi.org/10.1002/ana.20903
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
